BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+6.18%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$17.6B
AUM Growth
+$17.6B
(+1.3%)
Cap. Flow
-$34.5M
Cap. Flow
% of AUM
-0.2%
Top 10 Holdings %
Top 10 Hldgs %
87.48%
Holding
123
New
5
Increased
24
Reduced
7
Closed
6
Top Buys
| 1 |
Replimune Group
REPL
|
$34.6M |
| 2 |
Ascendis Pharma
ASND
|
$28.9M |
| 3 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$21.7M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$19.9M |
| 5 |
Nurix Therapeutics
NRIX
|
$18.1M |
Top Sells
| 1 |
Neurocrine Biosciences
NBIX
|
$63.5M |
| 2 |
Legend Biotech
LEGN
|
$63.4M |
| 3 |
Axsome Therapeutics
AXSM
|
$25.3M |
| 4 |
Merus
MRUS
|
$23.6M |
| 5 |
Sarepta Therapeutics
SRPT
|
$9.64M |
Sector Composition
| 1 | Healthcare | 99.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Alkermes
ALKS
$4.95B
| $44.7M | 0.25% |
1,500,000
| – | – |
|
|
CCXI
27
DELISTED
ChemoCentryx, Inc.
CCXI
| $44.4M | 0.25% |
1,792,657
+875,795
| +96% | +$21.7M |
|
|
KDNY
28
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $44.3M | 0.25% |
2,534,102
+200,000
| +9% | +$3.5M |
|
29
Insmed
INSM
$30.3B
| $42.5M | 0.24% |
2,156,001
| – | – |
|
30
Immatics
IMTX
$662M
| $38.5M | 0.22% |
4,423,731
| – | – |
|
|
DBVT
31
DBV Technologies
DBVT
$249M
| $37.3M | 0.21% |
1,461,426
| – | – |
|
|
JBIO
32
Jade Biosciences, Inc. Common Stock
JBIO
$245M
| $32.4M | 0.18% |
59,143
| – | – |
|
|
AMRN
33
Amarin Corp
AMRN
$311M
| $31.5M | 0.18% |
1,058,490
| – | – |
|
34
Verastem
VSTM
$585M
| $31.3M | 0.18% |
2,249,075
| – | – |
|
35
Ultragenyx Pharmaceutical
RARE
$3.04B
| $28.1M | 0.16% |
470,974
+26,530
| +6% | +$1.58M |
|
|
TSVT
36
DELISTED
2seventy bio
TSVT
| $27.2M | 0.15% |
2,062,744
| – | – |
|
37
Kiniksa Pharmaceuticals
KNSA
$2.63B
| $27.1M | 0.15% |
2,799,577
| – | – |
|
38
Biomea Fusion
BMEA
$114M
| $25.2M | 0.14% |
2,104,559
+553,114
| +36% | +$6.63M |
|
39
Altimmune
ALT
$325M
| $24.3M | 0.14% |
2,075,403
+1,003,365
| +94% | +$11.7M |
|
|
NVTA
40
DELISTED
Invitae Corporation
NVTA
| $24.1M | 0.14% |
9,873,488
| – | – |
|
41
Pacific Biosciences
PACB
$378M
| $24.1M | 0.14% |
5,444,963
| – | – |
|
42
Xenon Pharmaceuticals
XENE
$2.99B
| $22.9M | 0.13% |
751,639
| – | – |
|
43
Heron Therapeutics
HRTX
$204M
| $22.7M | 0.13% |
8,131,678
| – | – |
|
|
44
Merus
MRUS
$5.04B
| $22.5M | 0.13% |
995,397
-1,042,072
| -51% | -$23.6M |
|
|
VERV
45
DELISTED
Verve Therapeutics
VERV
| $21.6M | 0.12% |
1,416,530
| – | – |
|
46
Design Therapeutics
DSGN
$339M
| $20.1M | 0.11% |
1,436,636
| – | – |
|
|
AFMD
47
DELISTED
Affimed
AFMD
| $18.3M | 0.1% |
659,683
+144,366
| +28% | +$4M |
|
48
Instil Bio
TIL
$196M
| $18M | 0.1% |
194,685
| – | – |
|
|
OTIC
49
DELISTED
Otonomy, Inc.
OTIC
| $17.5M | 0.1% |
8,412,634
+567,942
| +7% | +$1.18M |
|
50
Denali Therapeutics
DNLI
$2.24B
| $17.3M | 0.1% |
588,738
+500,000
| +563% | +$14.7M |
|